Versifel FeLV
Active substance
ATC code
Species
Cats.
Indications
For active immunisation of susceptible cats from 9 weeks of age to reduce the number of cats infected with FeLV and presenting clinical signs of the related disease.
No data are available in the studies to demonstrate protection against related clinical disease but prevention of infection is associated with protection against related clinical disease.
Onset of immunity: four weeks after the completion of the primary vaccination course.
Duration of immunity: one year after the primary course and three years after the booster.
Dose to be administered and administration route
Subcutaneous use.
Shake the vial well immediately before use.
Primary vaccination:
Two doses of 1 mL should be administered subcutaneously to cats from nine weeks of age, with an interval of 3-4 weeks between doses.
Re-vaccination:
A single booster dose should be administered 1 year after the completion of the primary vaccination course. Thereafter a single booster dose should be administered to cats once every 3 years.
For concurrent vaccination with Zoetis’ Versifel CVR, a single dose of Versifel FeLV should be administered as described above. A single dose of Zoetis’ Versifel CVR should then be administered at a separate site via the subcutaneous route.
For simultaneous vaccination with Zoetis’ Versifel CVR, the contents of a single vial of Zoetis’Versifel CVR should be reconstituted with the contents of a single vial of Versifel FeLV in place of the diluent. Once mixed, the contents of the vial should appear as a slightly coloured (pink/orange) opaque suspension; the mixed vaccines should be injected immediately via the subcutaneous route.
Adverse reactions
Cats:
|
Common (1 to 10 animals / 100 animals treated): |
Injection site swelling1 Elevated temperature2, 3 |
|
Rare (1 to 10 animals / 10,000 animals treated): |
Enlarged lymph node (localised)4 |
|
Very rare (<1 animal / 10,000 animals treated, including isolated reports): |
Injection site pain Diarrhoea, Vomiting Allergic reaction, Anaphylactic shock5 Anorexia, Depression, Malaise6 |
1Small (diameter usually smaller than 10 mm, maximal diameter 20 mm) very rarely associated with a brief period of discomfort and/or pain. The majority of these swellings resolve within a short period (2 weeks). A small proportion may remain detectable for 1 to 2 months however, by this time they are very small.
2Expected to be of short duration (resolving within 48 hours). Frequency and duration of any temperature rise is usually lower following subsequent administrations.
3When administered concurrently or simultaneously with Zoetis’ Versifel CVR transient increases in temperature (up to 40.5 °C) are frequently observed following first vaccination lasting up to 5 days.
4Transient enlargement of the pre-scapular lymph node following the second dose administration, such enlargements are small in size (0.5 cm diameter) and only detected upon palpation of the area following injection.
5If such a reaction occurs appropriate treatment should be administered. 6Normally resolves within 24 hours.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See also section 16 of the package leaflet for contact details.
TRUSTED SOURCE
